MILV, let's make this real simple.
A share of MILV is a share in the research departments of the University of Pennsylvania and Children's Hospital of Philly that are working on a drug delivery system that will carry drugs pass the acidic gastric juices of the stomach and the blood brain barrier.
What's being transferred from University of Pennsylvania to MILV (NDT Pharmaceuticals INC).
Per SEC filings
CCA and the University of Pennsylvania ("PENN") and the Children's Hospital of Philadelphia ("Children's Hospital") are engaged in a co-development alliance which is combining CCA's NPC technology with other PENN and Children's Hospital technologies to co-develop technologies to be jointly owned by CCA, PENN and Children's Hospital, including compounds to treat, and to a certain extent, prevent traumatic brain injury. This alliance also entails development involving dendrites, neurodevelopment, bone morphogenetic proteins, glutamate excitotoxicity, neural regeneration, injury-induced altered brain excitability, circuit rearrangement and synaptic function, including the development of pharmaceuticals."
